Industry Briefs: December 10, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: December 10, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Amorfix Life Sciences has established a collaboration with CNJ Holdings, a wholly owned subsidiary of Cangene, for the identification and development of therapeutic antibodies against proprietary disease specific epitopes identified using Amorfix’s ProMIS discovery technology for treating various oncology indications. Read More

AMRI has extended its commercial supply relationship with GE Healthcare for aminobisamide hydrochloride. Read More

Impact Analytical announced an expansion that includes new testing and analysis laboratories. The project is scheduled to be completed by March 2013. Read More

Kemwell has signed an agreement with Mercury Pharma for the manufacturing of pharmaceuticals at its new production facility in Uppsala, Sweden. Read More

Sartorius Stedim Biotech has launched its Sartoguard NF prefilter series, featuring a combination of high-performance polyethersulfone membranes and nanofleece technology. Read More

People News

AAIPharma has appointed Timothy Rhines as senior director of biopharmaceutical Development. Read More

In addition, AAIPharma has also appointed David Browne director of analytical chemistry. Read More

AmerisourceBergen has named Peyton R. Howell senior vice-president of AmerisourceBergen Corporation, and president of global sourcing and manufacturer relationships. Read More

Pfizer has elected CEO Ian Read as chairman of the board. Read More

Roche has announced several changes to its board of directors, and has proposed CEO Severin Schwan as a new member of the board. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here